Please login to the form below

Not currently logged in
Email:
Password:

Dr Maurice Chagnaud appointed as new CEO of Polpharma

Will take the reins at the Polish pharmaceutical group week
Polpharma Maurice Chagnaud

Polish pharmaceutical group Polpharma has appointed Dr Maurice Chagnaud as its new CEO.

He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia & CIS.

Prior to that Dr Chagnaud held senior roles at Teva, Mylan and Merck Generics during a career that has so far seen him amass more than 20 years of European pharma management experience.

Polpharma operates across Europe, CIS and Central Asia and has manufacturing subsidiaries in Poland, Russia and Kazakhstan. It's the largest Polish pharmaceutical group and wants Dr Chagnaud to help it become a regional leader in CEE, CIS and Central Asia.

Jerzy Starak, chairman of Polpharma's supervisory board, said: “Polpharma's strategic goal is to become a regional leader and grow outside of our current boundaries. We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva and Lupin, where his achievements included building regional strategies and transforming organisations to meet new challenges.

“I am confident that he will manage Polpharma effectively, identify and pursue new opportunities, and motivate our team to deliver outstanding performance to secure the long-term growth of our group.”

As Polpharma CEO Dr Chagnaud will succeed Markus Sieger, who has been delegated by the Supervisory Board to exercise supervision over the company for the last six months, and who will remain a member of the Supervisory Board.

30th September 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...